Indio Labs (a subsidiary of Omya Healthcare Ltd.) is currently developing platform technology devices for soft-tissue core biopsy. The BioScoop™ Biopsy System, being developed in collaboration with the Stanford-India Biodesign Programme at the All India Institute of Medical Sciences (AIIMS), New Delhi, represents an exciting new approach to percutaneous aspiration solid organ biopsy. It is designed to enable physicians to achieve safer and definitive tissue capture using a novel needle design, advanced needle-tissue characterization, and automated control. In an exclusive first, BxSeal™ technology for controlled, concurrent delivery of hemostatic agents during the biopsy procedure for highly vascular organs. This allows for immediate hemostatic action against internal bleeding and shall provide a significant safety advantage over competitive devices. The seamless integration of BioScoop™ and BxSeal™ technologies shall provide consistent tissue samples with minimal risk of internal bleeding. The device has low requirements on operator skills and shall reduce the cost of the procedure, providing affordable definitive diagnosis to patients.